Navigation Links
ICx Technologies Works With Merck & Co., Inc. to Develop Cancer Diagnostic Technology
Date:12/3/2007

WASHINGTON and LA JOLLA, Calif., Dec. 3 /PRNewswire-FirstCall/ -- ICx Technologies (Nasdaq: ICXT), a developer of advanced technology solutions for homeland security and force protection, announced today a research study with Merck & Co., Inc. and Fred Hutchinson Cancer Research Center of Seattle.

The purpose of the study is to test and refine a set of protocols for detecting and recovering circulating nucleic acids from blood -- a key early detector for cancer treatment - in order to support the development of an investigational cancer therapy. The study is being conducted by its La Jolla, Calif.-based Biosystems unit with participation by the Hutchinson Center.

"We have a history of aggressive research and development expertise and we're pleased to work with Merck," said ICx CEO Hans Kobler. "By applying the rapid and data-rich molecular diagnosis technology developed for security applications, ICx is hoping to aid the development of a diagnostic tool to assist in the evaluation of cancer therapies."

For more information, visit http://www.icxt.com.

About ICx Technologies(TM)

ICx develops advanced technologies for effective security solutions. ICx sensors detect and identify chemical, biological, radiological, nuclear and explosive (CBRNE) materials. ICx surveillance products discern people and objects invisible to human senses and conventional cameras. ICx software and systems connect, command and control these security devices, while its intelligence and special-operations experts provide the unique insight that drives the company's innovation. ICx has manufacturing and research facilities in the United States, Canada and Europe.

Statements contained in this press release that are not historical facts are "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements, including statements relating to ICx Technologies' plans, objectives and expectations for future operations, are uncertain and subject to a variety of risks that could cause actual results to differ materially from those expected by ICx Technologies. You should consider the risk factors described in ICx Technologies' prospectus as filed with the U.S. Securities and Exchange Commission on November 8, 2007, as well as other filings. ICx Technologies undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

All trademarks, registered trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE ICx Technologies
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology: